Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cumberland Pharmaceuticals Receives Vizient Contract for Vibativ  | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cumberland Pharmaceuticals Receives Vizient Contract for Vibativ 

The Vibativ 4-Vial Starter Pak is an FDA-approved injectable antibiotic indicated to treat HABP/VABP and complicated skin and skin structure infections.

By: Rachel Klemovitch

Assistant Editor

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, now provides Vibativ (telavancin) 4-Vial Starter Pak through a new contract with Vizient, a provider-driven healthcare performance improvement company.

Through this agreement, Vizient members now have increased access to Vibativ’s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.

Vibativ is an FDA-approved injectable antibiotic indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.

Vizient serves over 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market.

In addition to the Vibativ 4-Vial Starter Pak, the Vibativ 12-vial carton is also available to Vizient provider clients through several distribution channels.

“We’re pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers, and outpatient centers nationwide,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics